Wellington Management Group LLP Has $6.80 Million Holdings in Progyny, Inc. (NASDAQ:PGNY)

Wellington Management Group LLP trimmed its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 394,129 shares of the company's stock after selling 36,171 shares during the period. Wellington Management Group LLP owned about 0.46% of Progyny worth $6,799,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PGNY. Signaturefd LLC raised its holdings in Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares during the last quarter. Caitlin John LLC grew its stake in Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Progyny in the fourth quarter valued at about $74,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PGNY. Canaccord Genuity Group lifted their target price on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, February 28th. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Bank of America increased their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Finally, BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research note on Monday, March 31st. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $23.64.

Progyny Price Performance

Shares of NASDAQ PGNY traded down $0.46 during mid-day trading on Wednesday, hitting $21.36. The company had a trading volume of 205,477 shares, compared to its average volume of 1,727,964. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $33.85. The firm has a market cap of $1.82 billion, a P/E ratio of 36.73, a PEG ratio of 2.39 and a beta of 1.33. The business's 50-day simple moving average is $21.99 and its 200-day simple moving average is $18.76.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.